TLX: Radiopharmaceuticals — Diagnostics Pays, Pipeline Decides
TLX: Radiopharmaceuticals — Diagnostics Pays, Pipeline Decides
In a Nutshell
Executive Summary
In a Nutshell
Telix Pharmaceuticals sells FDA-approved radioactive imaging agents used to detect prostate cancer and is simultaneously funding three Phase 3 clinical trials in cancer treatment. At A$10.43 vs fair value A$11.60, the stock is undervalued by 11%. That modest gap masks a binary outcome: the profitable diagnostics franchise is worth roughly A$7–8 per share on its own, but Phase 3 pipeline readouts due in 2027–28 add or erase A$3–4 from that number.
Investor Profiles
| Profile | Rating | Rationale |
|---|---|---|
| Income | ★☆☆☆☆ | No dividends are planned through at least FY28, and the group remains unprofitable at the net level through FY26. Free cash flow turns positive only in FY27. Not suitable for income investors. |
| Value | ★★★☆☆ | The stock is undervalued by 11% at A$10.43 vs fair value A$11.60, but the 90% confidence range spans A$7.16 to A$14.86 — genuine uncertainty, not precision. Margin of safety is modest; the diagnostics franchise alone supports roughly A$7–8, making entry below A$8.00 materially more attractive. |
| Growth | ★★★★☆ | Revenue grows 14–17% annually through FY28, compounding from US$804M toward US$1.25B. Free cash flow turns positive in FY27 at US$53M and reaches US$123M in FY28. The growth trajectory is commercially grounded, not speculative — but it is partly priced in at current levels. |
| Quality | ★★☆☆☆ | Group ROIC sits at 2.1% against a 12% cost of capital — a meaningful gap. The Precision Medicine segment earns well above 40% ROIC in isolation, but therapeutic R&D spending and distribution network startup losses drag the consolidated figure below the hurdle rate through FY27. |
| Thematic | ★★★★☆ | PSMA-PET imaging sits at roughly 45% U.S. penetration with a structural pathway to 70%+. Big Pharma validated the sector with US$11B in acquisitions across 2023–24. Telix is the only ASX-listed company with commercial-scale exposure to both diagnostic and therapeutic radiopharmaceuticals. |
Thematic investors are the natural fit. Radiopharmaceuticals are moving from niche to mainstream oncology — NCCN guideline adoption, Novartis Pluvicto's US$1B+ revenues, and US$11B in Big Pharma acquisitions confirm the shift is structural rather than cyclical. Telix is the only ASX-listed company with commercial-scale exposure to both sides of this trend. Patient capital with a 2–3 year horizon and tolerance for binary pipeline risk suits this stock best.
Executive Summary
Telix makes its money selling FDA-approved PSMA-PET imaging agents — Illuccix and Gozellix — that oncologists use to detect and stage prostate cancer. It is the only company with two CMS-reimbursed PSMA-PET products in the U.S., sharing the market in a duopoly with Lantheus. A January 2025 acquisition added a 30-site radiopharmacy network, giving Telix control from isotope production through to patient delivery.
FY25 revenue grew 56% to US$803.8M. The diagnostics segment generated US$216M in EBITDA at a 34.8% margin — the business engine that funds everything else. Group EBITDA fell to just US$39.5M after absorbing US$98M in therapeutic R&D spending and US$22M in distribution network startup losses.
The investment case has two distinct parts. The commercial diagnostics franchise is profitable, defensible, and growing at 14–17% annually — it stands on its own merits. Layered on top are three Phase 3 clinical trials in prostate, kidney, and brain cancers, worth roughly A$3–4 per share in risk-adjusted option value. A US$395M convertible bond maturing July 2029 connects both parts: the commercial business must accumulate sufficient cash to refinance it without diluting shareholders.
At A$10.43 vs fair value A$11.60, the stock is undervalued by 11%.
Results & Outlook
What happened?
FY25 was a year of deliberate investment, not underperformance. Revenue surged 56% to US$803.8M, driven by 20%+ organic growth in the diagnostics segment and 11 months of contribution from the newly acquired RLS radiopharmacy network. Group EBITDA fell from US$66.9M to US$39.5M — a counter-intuitive result explained entirely by accelerated R&D spending and startup losses in the new distribution business. The diagnostic engine itself performed strongly throughout the year.
| Metric | FY24A | FY25A | FY26E | FY27E |
|---|---|---|---|---|
| Revenue (US$M) | 516.6 | 803.8 | 942.0 | 1,097.0 |
| PM EBITDA (US$M) | — | 216.4 | 245.0 | 302.0 |
| Group EBITDA (US$M) | 66.9 | 39.5 | 69.0 | 136.0 |
| Net Profit (US$M) | — | (7.1) | (20.0) | 45.0 |
| Free Cash Flow (US$M) | — | (43.0) | (1.2) | 53.0 |
What's next?
Three near-term catalysts will test the thesis. Regulatory resubmissions for Zircaix (kidney cancer imaging) and Pixclara (prostate imaging) are expected in H2 2026 — both received FDA complete response letters citing manufacturing and data presentation issues rather than clinical failures, but a further rejection would damage confidence in Telix's regulatory execution. Management targets 16–18% diagnostic revenue growth for FY26, with the August H1 result the key confirmation point. The acquired distribution network targets breakeven in FY27–28, contributing US$16M in EBITDA by FY28 from a US$22M loss today. The thesis-defining event — Phase 3 interim data for TLX591-Tx in advanced prostate cancer — remains 18–24 months away and carries a A$3.50 per share binary swing in either direction.
Valuation & Risks
| Metric | Value |
|---|---|
| Fair Value | A$11.60 |
| Current Price | A$10.43 |
| Upside | +11.2% |
| Probability-Weighted Return | +5.6% |
| 90% Confidence Range | A$7.16 – A$14.86 |
| Bull Case (15% probability) | A$18.74 |
| Bear Case (25% probability) | A$7.12 |
What could go wrong?
The greatest single risk is a Phase 3 failure for TLX591-Tx, Telix's lead therapeutic candidate in advanced prostate cancer. A negative readout would eliminate roughly A$3.50 per share in pipeline value and simultaneously stress the US$395M convertible bond maturing in July 2029.
Telix holds US$142M in cash against that obligation today. The commercial business is accumulating cash — but the gap is real. If Phase 3 fails, investor confidence collapses, equity issuance becomes expensive, and a dilutive capital raise becomes likely. That scenario — modelled at 25% share count growth — reduces fair value to A$2.82.
The combined probability of Phase 3 failure cascading to financial stress sits around 20%. This is not a tail risk. It is a live scenario that position sizing must reflect.